RVNC insider transaction filings
Revance Therapeutics, Inc. — 44 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-02-06. Screen RVNC transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for RVNC between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Revance Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-02-06 | 4 | Gangolli Julian S — Director | Code (U): 30,106 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Foley Mark J — President & CEO, Director | Code (U): 996,935 @ $3.65 · Code (U): 110,913 @ $3.65 · Disposition to issuer (D): 27,933 · Grant/award (A): 84,686 @ $0 · Disposition to issuer (D): 84,686 | EDGAR |
| 2025-02-06 | 4 | Schilke Tobin — CFO | Code (U): 97,999 @ $3.65 · Disposition to issuer (D): 103,555 · Grant/award (A): 20,883 @ $0 · Disposition to issuer (D): 20,883 | EDGAR |
| 2025-02-06 | 4 | Moxie Dwight — CLO & GC | Code (U): 47,815 @ $3.65 · Disposition to issuer (D): 95,979 · Grant/award (A): 18,125 @ $0 · Disposition to issuer (D): 18,125 | EDGAR |
| 2025-02-06 | 4 | Hollander David — CMO & Global Therapeutics Lead | Code (U): 9,733 @ $3.65 · Disposition to issuer (D): 95,212 | EDGAR |
| 2025-02-06 | 4 | Jordan Erica — Chief Commercial Officer | Code (U): 6,922 @ $3.65 · Disposition to issuer (D): 107,942 | EDGAR |
| 2025-02-06 | 4 | Ware Olivia C — Director | Code (U): 16,675 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Kolaja Carey OConnor — Director | Code (U): 16,561 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Coric Vlad — Director | Code (U): 5,784 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Beraud Jill — Director | Code (U): 28,606 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Nolet Chris — Director | Code (U): 28,606 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-06 | 4 | Russell Angus C. — Director | Code (U): 36,506 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2025-02-05 | 4 | Foley Mark J — CEO, Director | Grant/award (A): 27,933 @ $0 | EDGAR |
| 2025-02-05 | 4 | Schilke Tobin — CFO | Grant/award (A): 6,888 @ $0 | EDGAR |
| 2025-02-05 | 4 | Moxie Dwight — CLO & GC | Grant/award (A): 5,979 @ $0 | EDGAR |
| 2025-01-03 | 4 | Schilke Tobin — CFO | Grant/award (A): 1,000 @ $2.18 | EDGAR |
| 2025-01-03 | 4 | Foley Mark J — CEO, Director | Grant/award (A): 1,000 @ $2.18 | EDGAR |
| 2024-11-19 | 4 | Hollander David — CMO & Global Therapeutics Lead | Sale (S): 3,908 @ $4.17 | EDGAR |
| 2024-07-02 | 4 | Foley Mark J — CEO, Director | Grant/award (A): 1,000 @ $2.18 | EDGAR |
| 2024-07-02 | 4 | Schilke Tobin — CFO | Grant/award (A): 1,000 @ $2.18 | EDGAR |
| 2024-05-03 | 4 | Ware Olivia C — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Russell Angus C. — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Nolet Chris — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Kolaja Carey OConnor — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Gangolli Julian S — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Coric Vlad — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Beraud Jill — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Jordan Erica — Chief Commercial Officer | Sale (S): 2,392 @ $3.80 | EDGAR |
| 2024-03-19 | 4 | Sjuts Dustin S — President | Tax withholding (F): 2,967 @ $5.30 · Sale (S): 9,211 @ $5.04 | EDGAR |
| 2024-03-19 | 4 | Moxie Dwight — CLO & GC | Tax withholding (F): 3,269 @ $5.30 · Sale (S): 8,125 @ $5.04 | EDGAR |
| 2024-03-19 | 4 | Schilke Tobin — CFO | Tax withholding (F): 3,822 @ $5.30 · Sale (S): 9,361 @ $5.04 | EDGAR |
| 2024-03-19 | 4 | Foley Mark J — CEO, Director | Tax withholding (F): 3,305 @ $5.30 · Tax withholding (F): 17,228 @ $5.30 | EDGAR |
| 2024-03-08 | 4 | Foley Mark J — CEO, Director | Purchase (P): 30,000 @ $6.98 | EDGAR |
| 2024-03-04 | 4 | Sjuts Dustin S — President | Grant/award (A): 22,110 @ $0 | EDGAR |
| 2024-03-04 | 4 | Moxie Dwight — CLO & GC | Grant/award (A): 15,143 @ $0 | EDGAR |
| 2024-03-04 | 4 | Schilke Tobin — CFO | Grant/award (A): 17,447 @ $0 | EDGAR |
| 2024-03-04 | 4 | Foley Mark J — CEO, Director | Grant/award (A): 70,750 @ $0 | EDGAR |
| 2024-02-02 | 4 | Moxie Dwight — SVP, GC & Secretary | Grant/award (A): 90,000 @ $0 · Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Schilke Tobin — CFO | Grant/award (A): 96,667 @ $0 · Grant/award (A): 145,001 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Foley Mark J — CEO, Director | Grant/award (A): 1,070,001 (derivative) @ $0 | EDGAR |
| 2024-01-03 | 4 | Sjuts Dustin S — President | Grant/award (A): 264 @ $7.47 | EDGAR |
| 2024-01-03 | 4 | Schilke Tobin — CFO | Grant/award (A): 434 @ $7.47 | EDGAR |
| 2024-01-03 | 4 | Foley Mark J — CEO, Director | Grant/award (A): 264 @ $7.47 | EDGAR |
| 2023-12-18 | 4 | Sjuts Dustin S — President | Tax withholding (F): 4,712 @ $8.08 | EDGAR |
Recent 8-K events — Revance Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-02-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-05 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RVNC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →